drugset / Trial / NCT01204086

Pharmacogenomics Studies of Antidepressants

NCT01204086

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to establish the clinical effectiveness of antidepressants by pharmacogenomic approach, and to determine the levels of inflammatory factors between the baseline and the end point of the study in Taiwanese major depressive disorder (MDD) patients.

Timeline

Start
2007-03
Primary completion
2010-12
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 20 mg
Subject Venlafaxine Small molecule 75 mg